SPY380.36-1.97 -0.52%
DIA309.45-4.53 -1.44%
IXIC13,192.35+72.96 0.56%

Press Release: Varex Announces Financial Results for First Quarter Fiscal Year 2021

· 02/04/2021 16:05
VAREX IMAGING CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Three Months Ended ---------------------------------------- (In millions, except for per share amounts) January 1, 2021 January 3, 2020 ------------------- ------------------- Revenues: Medical $ 139.2 $ 155.6 Industrial 37.9 44.5 --------------- --------------- Total revenues 177.1 200.1 Gross profit: Medical 44.1 43.8 Industrial 13.1 17.3 --------------- --------------- Total gross profit 57.2 61.1 Operating Expenses: Research and development 16.7 21.7 Selling, general and administrative 34.4 34.8 --------------- --------------- Operating expenses 51.1 56.5 --------------- --------------- Operating earnings: 6.1 4.6 --------------- --------------- Interest expense (10.3) (5.4) Other expense, net (0.5) (0.4) --------------- --------------- Interest and other expense, net (10.8) (5.8) --------------- --------------- Loss before taxes (4.7) (1.2) Income tax expense 1.6 -- --------------- --------------- Net loss (6.3) (1.2) Less: Net earnings attributable to noncontrolling interests 0.1 0.1 --------------- --------------- Net loss attributable to Varex $ (6.4) $ (1.3) === ========== === ========== Net loss per common share attributable to Varex Basic $ (0.16) $ (0.03) Diluted $ (0.16) $ (0.03) Weighted average common shares outstanding Basic 39.1 38.5 Diluted 39.1 38.5 VAREX IMAGING CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (In millions, except share amounts) January 1, 2021 October 2, 2020 ----------------- ----------------- Assets Current assets: Cash and cash equivalents $ 105.5 $ 100.6-- Revenues are expected to be between $180 million and $200 million -- Non-GAAP earnings per diluted share is expected to be between $0.05 and $0.25-- Revenues $177 million -- GAAP gross margin 32% | Non-GAAP gross margin* 34% -- GAAP operating expense $51 million | Non-GAAP operating expense* $46 million -- GAAP operating margin 3% | Non-GAAP operating margin* 8% -- GAAP net earnings $(0.16) per diluted share | Non-GAAP net earnings* $0.08 per diluted shareSALT LAKE CITY--(BUSINESS WIRE)--February 04, 2021--

Varex Announces Financial Results for First Quarter Fiscal Year 2021

Varex Imaging Corporation (Nasdaq: VREX) today announced its unaudited financial results for the first quarter of fiscal year 2021.

1QFY21 Summary

"Our financial results for the first quarter of fiscal year 2021 were stronger than our expectations," said Sunny Sanyal, Chief Executive Officer of Varex.

"Revenues increased 4% sequentially over the fourth quarter of fiscal year 2020, indicating the start of recovery in our business. Non-GAAP gross margin improved significantly to 34% and was sequentially higher by 580 basis points due primarily to the benefits from cost reductions, as well as a favorable shift in product mix in the medical segment. Non-GAAP operating expenses declined by about $3 million sequentially, reflecting our continued focus on profitability." Sanyal added.

Balance Sheet & Cash Flow

Cash flow from operations was $7 million for the first quarter of fiscal year 2021. Cash and cash equivalents improved to $106 million at the end of the first quarter.

Outlook

The following guidance is provided for the second quarter of fiscal year 2021:

Guidance for the company's net earnings per diluted share is provided on a non-GAAP basis only. This non-GAAP financial measure is forward-looking, and the company is unable to provide a meaningful or accurate GAAP forecast of net earnings per diluted share without unreasonable effort due to the uncertainty of amounts and timing of unusual items, such as restructuring costs.

Non-GAAP Financial Measures

*Please refer to "Reconciliation between GAAP and non-GAAP Financial Measures" below for a reconciliation of non-GAAP items to the comparable GAAP measures.

Conference Call Information

Varex will conduct its earnings conference call for the fourth quarter and fiscal year 2020 today at 3:00 p.m. Mountain Time. The conference call, including a supplemental slide presentation, will be webcast live and can be accessed at Varex's website at investors.vareximaging.com. Access will also be available by dialing 877-524-8416 from anywhere in the U.S. or by dialing 412-902-1028 from non-U.S. locations. The webcast and supplemental slide presentation will be archived on Varex's website. A replay of the call will be available from today through February 18th at 877-660-6853 from anywhere in the U.S. or 201-612-7415 from non-U.S. locations. The replay access code is 13715201.

About Varex

Varex Imaging Corporation is a leading innovator, designer and manufacturer of X-ray imaging components, which include X-ray tubes, digital detectors and other image processing solutions that are key components of X-ray imaging systems. With a 70+ year history of successful innovation, Varex's products are used in medical imaging as well as in industrial and security imaging applications. Global OEM manufacturers incorporate Varex's X-ray sources, digital detectors, connecting devices and imaging software in their systems to detect, diagnose, protect and inspect. Headquartered in Salt Lake City, Utah, Varex employs approximately 2,000 people located in North America, Europe, and Asia. For more information visit vareximaging.com.

Forward Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements concerning unaudited financial results; the impact of COVID-19 on Varex's business; benefits of current and future restructurings and other cost reduction actions; industry or market outlook; customer demand; potential impact of tariffs, revenues, product volumes, or other expected future financial results or performance; and any statements using the terms "believe," "expect," "intend," "outlook," "future," "anticipate," "will," "could," "estimate, " "guidance," or similar statements are forward-looking statements that involve risks and uncertainties that could cause Varex's actual results to differ materially from those anticipated. While forward-looking statements are based on assumptions and analyses made by us that we believe to be reasonable under the circumstances, whether actual results and developments will meet our expectations and predictions depend on a number of risks and uncertainties which could cause our actual results, performance, and financial condition to differ materially from our expectations. Such risks and uncertainties include the severity and duration of the COVID-19 pandemic and its impact on both the global economy and the Varex's business; our ability to maintain compliance with our financial covenants; shifts in product mix; not receiving the intended benefit of current or future restructurings or cost reduction actions; the continued impact of tariffs or a global trade war on Varex's products and customer purchasing patterns; global economic conditions; demand for and delays in delivery of products of Varex or its customers; litigation costs; Varex's ability to develop, commercialize and deploy new products; the impact of reduced or limited demand by purchasers of certain X-ray products; the impact of competitive products and pricing; the ability to remediate material weaknesses in internal control; and the other risks listed from time to time in our filings with the U.S. Securities and Exchange Commission, which by this reference are incorporated herein. Any forward-looking statements made by us in this news release speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. Varex assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events, or otherwise.

Varex has not filed its Form 10-Q for the first quarter of fiscal year 2021. All financial results described here should be considered preliminary, and are subject to change to reflect any necessary adjustments or changes in accounting estimates, that are identified prior to the time Varex files the Form 10-Q.

(MORE TO FOLLOW) Dow Jones Newswires

February 04, 2021 16:05 ET (21:05 GMT)